Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Pirfenidone Capsules had estimated annual sales of USD 95 million in the US
This product will be manufactured at Lupin's Pithampur facility in India
The company has entered into a three-year Deferred Prosecution Agreement
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Oteseconazole Capsules were found to be safe and more effective than fluconazole
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
Subscribe To Our Newsletter & Stay Updated
